Mezagitamab
Mezagitamab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 1 | 2 | — | — | 3 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | 1 | — | 2 | — | — | 3 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | 1 | — | — | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | 1 | — | — | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 2 | — | — | 2 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | 2 | — | — | 2 |
| Immune system diseases | D007154 | — | D89.9 | — | — | 2 | — | — | 2 |
| Blood platelet disorders | D001791 | — | — | — | — | 2 | — | — | 2 |
| Thrombocytopenic purpura | D011696 | — | — | — | — | 2 | — | — | 2 |
| Purpura | D011693 | HP_0000979 | D69.2 | — | — | 2 | — | — | 2 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 3 | 2 | — | — | — | 3 |
| Plasma cell neoplasms | D054219 | — | — | 3 | 2 | — | — | — | 3 |
| Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | — | 1 | — | — | — | 1 |
| Muscle weakness | D018908 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 1 | — | — | — | — | 1 |
| Glomerulonephritis | D005921 | — | N05 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mezagitamab |
| INN | mezagitamab |
| Description | Mezagitamab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1. |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297833 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 0XMR8L9LOL (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CD38
CD38
Organism
Homo sapiens
Gene name
CD38
Gene synonyms
NCBI Gene ID
Protein name
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
Protein synonyms
2'-phospho-ADP-ribosyl cyclase, 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase, 2'-phospho-cyclic-ADP-ribose transferase, ADP-ribosyl cyclase 1, ADPRC 1, cADPR hydrolase 1, CD38, CD38 antigen (p45), cluster of differentiation 38, Cyclic ADP-ribose hydrolase 1, ecto-nicotinamide adenine dinucleotide glycohydrolase, NAD(+) nucleosidase, T10
Uniprot ID
Mouse ortholog
Cd38 (12494)
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (Q8BFY8)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Mezagitamab – Xoma
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 95 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use